Eos Management L.P. boosted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 55.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,567 shares of the conglomerate's stock after acquiring an additional 14,537 shares during the quarter. Danaher accounts for approximately 3.7% of Eos Management L.P.'s investment portfolio, making the stock its 6th biggest position. Eos Management L.P.'s holdings in Danaher were worth $8,316,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. FAS Wealth Partners Inc. raised its position in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares in the last quarter. Horizon Financial Services LLC grew its stake in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Danaher by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Compass Wealth Management LLC boosted its position in Danaher by 17.4% during the first quarter. Compass Wealth Management LLC now owns 39,764 shares of the conglomerate's stock worth $8,152,000 after purchasing an additional 5,891 shares in the last quarter. Finally, Palisade Capital Management LP increased its position in shares of Danaher by 1.3% in the first quarter. Palisade Capital Management LP now owns 136,993 shares of the conglomerate's stock valued at $28,084,000 after buying an additional 1,736 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the company. Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Robert W. Baird dropped their price target on Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. UBS Group cut their price target on Danaher from $275.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Jefferies Financial Group cut their price target on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Finally, Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $248.43.
View Our Latest Report on Danaher
Insider Activity
In other news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is owned by corporate insiders.
Danaher Trading Down 0.3%
NYSE:DHR traded down $0.71 on Friday, hitting $204.80. 2,369,010 shares of the stock were exchanged, compared to its average volume of 3,508,130. The stock has a market cap of $146.57 billion, a PE ratio of 39.77, a PEG ratio of 2.88 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average of $196.05 and a 200-day moving average of $206.30. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. As a group, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.
Danaher Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.63%. Danaher's payout ratio is 24.85%.
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
